IRWD

Ironwood Pharmaceuticals, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · ironwoodpharma.com

$4.59

Mkt Cap $748.4M

52w Low $0.53 77.3% of range 52w High $5.78

50d MA $3.67 200d MA $2.81

P/E (TTM) 29.6x

EV/EBITDA 8.9x

P/B —

Debt/Equity -2.3x

ROE 0.9%

P/FCF 4.3x

RSI (14) —

ATR (14) —

Beta 0.17

50d MA $3.67

200d MA $2.81

Avg Volume 2.8M

About

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as u…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	0.02	-0.01	-150.0%	3.36	+3.9%	+8.9%	+1.8%	+6.2%	+8.3%	+11.3%	—
Nov 10, 2025	AMC	0.09	0.24	+166.7%	2.53	-1.2%	+14.2%	+22.9%	+33.2%	+24.1%	+23.7%	—
Aug 7, 2025	AMC	-0.02	0.14	+800.0%	0.88	+0.0%	+1.9%	-5.0%	+11.6%	+23.9%	+21.6%	—
May 7, 2025	AMC	-0.05	-0.14	-180.0%	0.79	-2.4%	-11.6%	-10.5%	-7.3%	-13.6%	-18.1%	—
Feb 27, 2025	AMC	0.10	0.02	-80.0%	1.62	+0.6%	-0.6%	-6.2%	-8.0%	-4.9%	-4.3%	—
Nov 7, 2024	AMC	0.08	0.02	-75.0%	4.66	+1.3%	+6.4%	+2.6%	-5.8%	-7.5%	-11.8%	—
Aug 8, 2024	AMC	0.15	-0.01	-103.6%	4.05	+2.0%	+4.7%	+4.7%	+10.9%	+7.2%	+9.9%	—
May 9, 2024	AMC	0.18	-0.02	-111.1%	6.74	+1.0%	+3.9%	-0.7%	-1.6%	-2.7%	-1.5%	—
Feb 15, 2024	AMC	0.21	-0.01	-104.8%	14.99	-0.1%	-2.7%	-1.1%	+1.0%	-0.9%	+0.5%	—
Nov 9, 2023	AMC	0.16	0.09	-43.8%	9.52	+1.6%	+2.3%	-1.4%	+2.4%	+2.5%	-0.8%	—
Aug 8, 2023	AMC	0.25	0.31	+24.0%	10.31	+0.0%	-6.8%	-5.8%	-2.3%	-2.8%	-4.4%	—
May 4, 2023	AMC	0.24	0.25	+4.2%	10.58	+0.9%	+0.9%	-0.7%	-3.0%	-1.5%	-3.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 26	Citizens	Maintains	Market Outperform → Market Outperform	—	$3.36	$3.49	+3.9%	+8.9%	+1.8%	+6.2%	+8.3%	+11.3%
Jan 5	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$4.27	$4.51	+5.6%	+7.5%	+0.7%	-4.4%	-6.8%	-4.9%
Jan 5	Citizens	Upgrade	Market Perform → Market Outperform	—	$4.27	$4.51	+5.6%	+7.5%	+0.7%	-4.4%	-6.8%	-4.9%
Nov 11	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$2.53	$2.50	-1.2%	+14.2%	+22.9%	+33.2%	+24.1%	+23.7%
Apr 15	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$0.65	$0.61	-5.4%	+11.5%	+15.8%	+12.2%	+8.8%	+11.0%
Apr 15	Jefferies	Downgrade	Buy → Hold	—	$0.65	$0.61	-5.4%	+11.5%	+15.8%	+12.2%	+8.8%	+11.0%
Apr 14	Leerink Partners	Maintains	Market Perform → Market Perform	—	$0.95	$0.70	-26.4%	-31.5%	-23.6%	-20.7%	-23.1%	-25.4%
Jan 30	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.72	$3.30	-11.3%	-38.2%	-37.1%	-43.5%	-41.4%	-43.3%
Jan 22	Craig-Hallum	Maintains	Buy → Buy	—	$3.79	$3.75	-1.1%	-1.8%	-0.5%	-2.1%	+0.3%	+0.3%
Aug 9	Wells Fargo	Maintains	Overweight → Overweight	—	$4.05	$4.13	+2.0%	+4.7%	+4.7%	+10.9%	+7.2%	+9.9%
Aug 9	Craig-Hallum	Maintains	Buy → Buy	—	$4.05	$4.13	+2.0%	+4.7%	+4.7%	+10.9%	+7.2%	+9.9%
May 10	Craig-Hallum	Maintains	Buy → Buy	—	$6.74	$6.81	+1.0%	+3.9%	-0.7%	-1.6%	-2.7%	-1.5%
Mar 1	Wells Fargo	Maintains	Overweight → Overweight	—	$9.43	$9.29	-1.5%	-3.8%	-1.1%	-1.2%	-8.6%	-5.3%
Feb 16	Piper Sandler	Maintains	Overweight → Overweight	—	$14.99	$14.97	-0.1%	-2.7%	-1.1%	+1.0%	-0.9%	+0.5%
May 23	Piper Sandler	Maintains	Overweight → Overweight	—	$10.85	$11.00	+1.4%	+1.1%	-0.4%	-1.1%	-0.4%	-0.9%
Aug 29	Piper Sandler	Maintains	Overweight → Overweight	—	$11.14	$11.15	+0.1%	-2.2%	-2.5%	-3.4%	-2.8%	-2.3%
Aug 16	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$11.91	$12.02	+0.9%	+0.8%	-1.7%	-0.5%	+0.2%	-2.9%
Apr 22	Piper Sandler	Maintains	Overweight → Overweight	—	$11.78	$11.98	+1.7%	+3.4%	+3.4%	+0.3%	+0.9%	+0.9%
Oct 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$13.77	$13.83	+0.4%	+0.6%	-1.6%	-0.9%	-0.8%	-2.6%
Jul 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$12.57	$12.65	+0.6%	-0.6%	+0.2%	+2.2%	+5.5%	+3.3%
Feb 22	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$9.54	$9.54	+0.0%	-1.9%	-0.6%	-2.5%	-5.2%	-3.2%
Feb 19	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$9.32	$9.34	+0.2%	+2.4%	+0.4%	+1.7%	-0.2%	-3.0%
Nov 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.01	$10.57	+5.6%	+6.6%	+7.6%	+15.1%	+15.5%	+15.5%
Nov 6	Credit Suisse	Maintains	Neutral → Neutral	—	$10.01	$10.57	+5.6%	+6.6%	+7.6%	+15.1%	+15.5%	+15.5%
Sep 30	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$9.42	$8.96	-4.9%	-4.5%	-1.5%	-1.2%	-0.6%	+0.8%
Aug 7	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.09	$10.09	+0.0%	+1.1%	+0.8%	-1.6%	+0.4%	+1.4%
Jul 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.22	$10.36	+1.4%	+1.2%	+0.2%	+1.3%	+3.7%	-3.5%
Jun 1	Credit Suisse	Maintains	Neutral → Neutral	—	$9.73	$9.73	+0.0%	-0.1%	+7.5%	+3.3%	+0.6%	+2.2%
May 11	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$10.19	$10.03	-1.6%	+5.6%	+5.0%	+3.5%	+6.0%	+9.2%
May 7	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.40	$10.30	-1.0%	-2.3%	-2.0%	+3.5%	+2.9%	+1.4%
Apr 30	Wells Fargo	Maintains	Overweight → Overweight	—	$10.23	$10.09	-1.4%	-2.2%	-5.8%	-0.3%	+2.6%	+1.7%
Apr 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.58	$10.28	-2.8%	-5.4%	-4.3%	-2.5%	-2.6%	-4.5%
Mar 27	Morgan Stanley	Upgrade	Underweight → Equal Weight	—	$13.29	$13.49	+1.5%	-4.0%	-4.3%	+1.8%	+5.5%	-7.4%
Feb 25	HC Wainwright & Co.	Upgrade	Sell → Neutral	—	$14.25	$14.43	+1.3%	+1.8%	-1.2%	+1.2%	-0.1%	+3.9%
Feb 25	H.C. Wainwright	Upgrade	Sell → Neutral	—	$14.25	$14.43	+1.3%	+1.8%	-1.2%	+1.2%	-0.1%	+3.9%
Jan 24	JP Morgan	Upgrade	Underweight → Neutral	—	$12.42	$13.00	+4.7%	+0.6%	+3.5%	+0.0%	+3.9%	+7.1%
Nov 7	JP Morgan	Downgrade	Neutral → Underweight	—	$12.78	$12.32	-3.6%	-6.7%	-5.5%	-7.0%	-11.8%	-10.5%
Nov 6	Credit Suisse	Downgrade	Outperform → Neutral	—	$14.13	$13.50	-4.5%	-9.6%	-15.6%	-14.5%	-15.9%	-20.2%
Aug 9	Wells Fargo	Maintains	Outperform → Outperform	—	$18.97	$19.08	+0.6%	+1.3%	-0.8%	+0.0%	-0.6%	-2.0%
Jul 23	H.C. Wainwright	Maintains	Sell → Sell	—	$20.02	$19.75	-1.3%	-0.2%	-2.1%	-4.3%	-5.1%	-7.7%
Jul 18	Cowen & Co.	Downgrade	Outperform → Market Perform	—	$21.07	$20.23	-4.0%	-5.6%	-4.8%	-5.0%	-5.2%	-7.0%
May 31	Wells Fargo	Maintains	Outperform → Outperform	—	$17.41	$17.61	+1.1%	+6.7%	+5.5%	+2.0%	+0.2%	+2.6%
May 9	Morgan Stanley	Downgrade	Equal Weight → Underweight	—	$18.38	$17.36	-5.5%	-4.5%	-3.4%	+0.9%	+0.8%	-0.4%
May 3	Barclays	Maintains	Equal Weight → Equal Weight	—	$18.91	$18.79	-0.6%	-3.0%	-1.7%	-5.0%	-2.8%	-7.2%
May 2	Mizuho	Upgrade	Neutral → Buy	—	$18.69	$19.11	+2.2%	+1.2%	-1.8%	-0.5%	-3.9%	-1.7%
Jan 5	Bank of America	Downgrade	Buy → Underperform	—	$15.20	$14.56	-4.2%	-0.4%	-5.9%	-6.8%	-8.9%	-0.7%
Jan 5	BofA Securities	Downgrade	Buy → Underperform	—	$15.20	$14.56	-4.2%	-0.4%	-5.9%	-6.8%	-8.9%	-0.7%
Dec 6	Mizuho	Downgrade	Buy → Neutral	—	$15.80	$15.17	-4.0%	-4.3%	-4.5%	-2.0%	-3.1%	-1.2%
Nov 27	Credit Suisse	Maintains	Outperform → Outperform	—	$15.64	$15.84	+1.3%	+3.8%	+6.2%	+9.5%	+10.4%	+10.7%
Jul 21	JP Morgan	Downgrade	Overweight → Neutral	—	$17.00	$17.00	+0.0%	+1.3%	+0.6%	+0.2%	+0.6%	-2.1%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

I cannot provide a meaningful analysis because the filing summary contains only technical metadata and schema references with no actual business information about Irwood (IRWD).

Mar 11

8-K

Ironwood Pharmaceuticals, Inc. - Class A -- 8-K Filing

Ironwood Pharmaceuticals raised 2026 guidance to $1.125-$1.175 billion in net sales and over $300 million adjusted EBITDA, while advancing apraglutide Phase 3 trials for short bowel syndrome beginning Q2 2026.

Feb 25

Data updated apr 25, 2026 4:18pm · Source: massive.com